Antiemetics
High-yield Verified · Oct 2026Prototype: ondansetron
Antiemetics are a class of medications used for chemotherapy-induced nausea and vomiting.
The 5-HT3 receptor antagonists (setrons, stem -setron) are the workhorse antiemetics. Other classes (D2, NK1, antihistamines) act at different sites — learn where each one works.
How it works in the body
The system involved, what goes wrong, and how the drug and body interact.
01 What actually triggers vomiting — the serotonin signal
Vomiting is a reflex, coordinated by a "vomiting center" in the brainstem that receives inputs from several sources: a chemical-sensing area called the chemoreceptor trigger zone (CTZ / area postrema) that samples the blood, the gut via the vagus nerve, the inner ear (motion), and higher brain centers (smells and other senses, psychological distress, and anticipation — anticipatory nausea can be triggered by the sights and smells of the treatment room). Different antiemetics work by silencing different inputs — which is why the right drug depends on why the patient is nauseated.
For chemotherapy, radiation, and surgery, a key culprit signal is serotonin (5-HT). These insults make enterochromaffin cells in the gut release serotonin, which fires 5-HT3 receptors on the vagal afferent nerves in the gut wall; that signal travels up the vagus to the brainstem and also acts on 5-HT3 receptors centrally in the CTZ. The setrons block those 5-HT3 receptors at both ends — peripherally in the gut (thought to be the main site) and centrally — cutting the emetic signal off at its source.
02 One vomiting center, several drug classes — know the map
Because so many inputs feed the vomiting center, the antiemetics are best learned as a map of sites. The setrons (5-HT3) own chemo, radiation, and post-op nausea. Dopamine D2 antagonists — metoclopramide, prochlorperazine, promethazine — block the CTZ (metoclopramide also speeds gastric emptying). NK1 (substance-P) antagonists, the -pitants (aprepitant), are added to setrons for the most emetogenic chemo. Antihistamines and anticholinergics (meclizine, scopolamine) target the inner-ear/motion pathway — note the setrons are largely ineffective for motion sickness because that route isn’t serotonin-driven. Dexamethasone is a common partner in chemo regimens, and cannabinoids (dronabinol, nabilone) are a limited-use option.
A practical detail that follows from the pharmacology: setrons work best given prophylactically — before the emetogenic stimulus (before chemo; around anesthesia for surgery) — because vomiting is easier to prevent than to treat once it starts. Within the class, palonosetron is second-generation with a long half-life (~40 h), useful for delayed chemo nausea; and dolasetron’s IV form is contraindicated for chemo nausea over QT concerns, which is the perfect segue to the class’s signature risk.
Dolasetron is no longer marketed in the US: Drugs@FDA lists both Anzemet applications — tablets and injection — as discontinued, and there is no other US dolasetron product (a 2023 tablet label is still posted on DailyMed). Its QT and heart-block lessons still apply, and current references such as the 2026 CPIC pharmacogenomic guideline still list dolasetron among the 5-HT3 antagonists, so learners will meet the name.
03 Why the QT warning follows — and the 32 mg story
The signature danger of the setrons is on the heart: they can prolong the QT interval, and ondansetron does this in a dose-dependent way. A longer QT means the ventricles take longer to reset electrically, which can degenerate into Torsades de Pointes, a life-threatening arrhythmia. The risk climbs with higher doses, with other QT-prolonging drugs, and with low potassium or magnesium — which is exactly why nurses correct electrolytes before dosing and are cautious in patients with congenital long-QT syndrome.
This isn’t theoretical. After a thorough-QT study, the FDA found that a single 32 mg IV dose of ondansetron prolonged the QT enough to be unsafe, and in 2012 that 32 mg IV dose was removed from the market — the maximum single IV dose is now 16 mg. (Oral dosing was not changed.) A second thing to know: setrons add to the body’s serotonin load, so combined with SSRIs, SNRIs, or MAOIs they carry a labeled risk of serotonin syndrome. Despite these real warnings, the setrons carry no boxed warning, and ondansetron’s formal contraindications are just two: apomorphine (profound hypotension) and hypersensitivity.
Drug names
Indications
- Chemotherapy-induced nausea & vomiting (CINV) — including delayed CINV (palonosetron)
- Radiation-induced nausea & vomiting
- Postoperative nausea & vomiting (PONV) — prophylaxis around anesthesia, or treatment once it starts
- Off-label: acute gastroenteritis, refractory nausea of pregnancy
Mechanism of action
5-HT3 (serotonin-3) receptor antagonists competitively block 5-HT3 receptors at two sites: peripherally on vagal afferent nerve terminals in the GI tract (thought to be the main action) and centrally in the chemoreceptor trigger zone/area postrema. Chemotherapy, radiation, and surgery cause gut enterochromaffin cells to release serotonin, which would otherwise fire these receptors and trigger the emetic reflex; blocking them interrupts the signal at its source.
Therapeutic effects — what you'll see working
Prevention is easier than rescue: given before chemo or radiation, or around anesthesia, setrons stop the emetic signal before it builds. Judge success by the absence or marked reduction of nausea and vomiting episodes.
- Prevention of chemo/radiation nausea & vomiting
- Blocking the 5-HT3 receptors that gut serotonin would fire prevents the acute wave of nausea and vomiting after emetogenic chemo or radiation — most effective when given before treatment. Success is simply the patient not vomiting.
- Prevention of postoperative nausea & vomiting
- A dose timed around anesthesia (ondansetron just before induction; granisetron at the end of surgery) blocks the emetic signal from anesthesia and the procedure, reducing PONV in the recovery period — a common, targeted use of a single IV dose.
- Control of delayed nausea (palonosetron)
- Palonosetron’s long half-life (~40 h) and high receptor affinity extend coverage into the delayed phase (days 2–5) of chemo nausea, where shorter-acting setrons fall short.
Adverse effects
The common setron effects are headache and constipation. The serious risk to watch is the cardiac one — dose-dependent QT prolongation (ondansetron) worsened by low K⁺/Mg²⁺ and other QT drugs — plus additive serotonin syndrome. The setrons carry no boxed warning; the dopamine-antagonist antiemetic metoclopramide (mapped above) is the exception — it carries a tardive-dyskinesia boxed warning (below).
Interactions
Contraindications
Only two are formal contraindications (apomorphine, hypersensitivity); congenital long-QT is a strong "avoid" caution rather than an absolute bar, and the QT-drug/electrolyte cautions are what nursing acts on.
Nursing considerations
The RN-specific layer — each action paired with the reason it matters.
Common questions
What are Antiemetics used for?
How do Antiemetics work?
What are the serious side effects of Antiemetics?
Conditions treated
[TMZ] "To reduce nausea and vomiting, take TEMODAR on an empty stomach or at bedtime" and consider antiemetic therapy before and after each dose (label). [CRAN] "Postoperative nausea and vomiting (PONV) prophylaxis" is part of the craniotomy bundle. No specific antiemetic is named in the sources.
Nausea and vomiting are named class toxicities of chemotherapy, and the mechanism is the same one behind everything else on this page: the agents hit the rapidly multiplying cells of the gastrointestinal tract. The disorder-side reason to treat emesis aggressively is not comfort alone. The same gastrointestinal toxicity produces mucositis, and severe mucositis means "the dose in the subsequent chemotherapy cycle may have to be DECREASED OR DELAYED, affecting patients’ quality of life and WORSENING PROGNOSIS" — while "In severe cases, this can lead to parenteral nutrition." Controlling the gut protects the treatment plan and the nutrition that mucositis risk depends on, since "the frequency of mucositis is higher in patients with poor nutritional status." A patient who cannot keep fluids or food down is also a patient who cannot take oral medicines, which puts the rest of the regimen at risk. The class page owns the agents and their receptor targets.
Nausea and vomiting are listed chemotherapy and end-of-life effects in ovarian cancer (StatPearls); the sources name no specific antiemetic — role only.
Chemotherapy nausea and vomiting. "Gastrointestinal toxicities, which are common with chemotherapy, necessitate a comprehensive approach to symptom management. This includes using antiemetics to control nausea and vomiting."
Doxylamine–pyridoxine (Diclegis) — "indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management," but "DICLEGIS has not been studied in women with hyperemesis gravidarum." Take on an empty stomach, swallowed whole, daily (not as needed); causes somnolence — no driving until cleared and no alcohol or other CNS depressants; "Women should not breastfeed while using DICLEGIS." Ondansetron — off-label in pregnancy; StatPearls: "It should only be used when other medications have been trialed and failed." Label: birth-defect studies "have reported inconsistent findings"; QT prolongation (ECG monitoring is recommended with "electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia)"); serotonin syndrome, especially with other serotonergic drugs.
Chemotherapy nausea — "Usually, anti-emetic serotonin receptor antagonists or benzodiazepines, among other agents, are used for treatment and prophylaxis."
[Ménière’s] Attacks — NHS: "medicines to help symptoms such as vertigo, feeling sick (nausea) and being sick (vomiting)"; NIDCD: "Prescription drugs can help relieve dizziness and shorten the attack, particularly when taken soon after the dizziness starts." NHS: "keep your medicines with you at all times."
Metoclopramide, prochlorperazine or chlorpromazine are used with an NSAID or triptan, especially in the ED — they treat nausea and also have an analgesic effect.
Bortezomib GI effects — "Nausea, diarrhea, constipation, and vomiting may require use of antiemetic and antidiarrheal medications or fluid replacement."
Delayed gastric emptying after a Whipple is managed with nasogastric decompression, feeding support and "prokinetic agents like metoclopramide." Nausea and vomiting are also disease symptoms.
Metoclopramide is contraindicated — it "can induce hypertensive crisis." Dopamine receptor antagonists as a group are named crisis triggers, so check any antiemetic order.
Not comfort care — volume protection. The sourced symptomatic regimen for opioid withdrawal is specific by symptom: "nausea/vomiting: ondansetron, prochlorperazine, and promethazine," alongside "loperamide for diarrhea… and ibuprofen for myalgia." The disorder-side rationale is what makes this a nursing priority rather than a convenience: "clients who have associated diarrhea, vomiting, or sweating should be monitored for dehydration and have fluid levels maintained with oral and/or intravenous fluids." Controlling the vomiting is how the nurse prevents the volume loss, and volume loss is one of the two sourced hazards of opioid withdrawal — the other being the collapse of tolerance that follows it. The environment does some of this work too: "a calm, quiet environment with supportive and reassuring staff is instrumental for helping clients overcome most symptoms of acute opioid withdrawal and can decrease the need for pharmacologic interventions," with warm baths, rehydration and gentle stretching named for muscle aches and cramps. The class page owns the antiemetic pharmacology; this page teaches which symptom gets which agent and why the vomiting matters.
See also
Irreversibly shut off the stomach’s acid pump — the most powerful acid suppressors. Take before the first meal; think about long-term effects and the clopidogrel interaction.
Block the histamine (H2) arm of acid secretion — milder and faster than PPIs but shorter-acting and prone to tolerance. Famotidine is now one of the most commonly used agents; cimetidine has many interactions.
Promote elimination by several distinct mechanisms. The universal nursing rule: rule out bowel obstruction before giving any laxative.
Neutralize stomach acid for fast, short heartburn relief. Separate from other drugs; mind the bowel effects.
Slow the gut to control diarrhea — but rule out infection first. High-dose loperamide is cardiotoxic.
Locally acting anti-inflammatories that induce and maintain remission in inflammatory bowel disease. Sulfasalazine’s sulfa half drives its side effects.
Sources
- Ondansetron injection — QT/Torsades warning, apomorphine contraindication, 16 mg max single IV dose (FDA label) — FDA / DailyMed
- FDA Drug Safety Communication — 32 mg single IV ondansetron dose removed (QT prolongation), Dec 2012 (archived copy) — U.S. FDA (archived)
- Antiemetics — Selective 5-HT3 Antagonists — mechanism, sites of action & adverse effects — StatPearls (NCBI)
- Ondansetron — indications, dosing & adverse effects — StatPearls (NCBI)
- Metoclopramide — tardive-dyskinesia boxed warning, 12-week limit — StatPearls (NCBI)
- Ondansetron tablets / orally disintegrating tablets — FDA label (dosing, phenylalanine, mechanism) — DailyMed (NLM)
- ANZEMET (dolasetron) tablets — IV contraindicated for chemo nausea; correct K/Mg first (FDA label) — DailyMed (NLM)
- Palonosetron injection — ~40 h half-life, acute and delayed CINV (FDA label) — DailyMed (NLM)
- REGLAN (metoclopramide) — tardive dyskinesia boxed warning (FDA label) — DailyMed (NLM)
- EMEND (aprepitant) — NK1 antagonist with other antiemetics for emetogenic chemo (FDA label) — DailyMed (NLM)
- SANCUSO (granisetron transdermal system) — FDA label — DailyMed (NLM)
- SUSTOL (granisetron extended-release injection) — FDA label — DailyMed (NLM)
- Drugs@FDA marketing status — Zofran, Aloxi, Anzemet, Sancuso, Sustol — U.S. FDA (openFDA)
- Antiemetic Medications — classes and sites of action — StatPearls (NCBI)
- Motion Sickness — vestibular pathway, scopolamine and antihistamines — StatPearls (NCBI)
- Antiemetic Histamine H1 Receptor Blockers — promethazine dopamine antagonism — StatPearls (NCBI)
- Antiemetic Neurokinin-1 Receptor Blockers — delayed CINV, combination with setrons — StatPearls (NCBI)
- Scopolamine — vomiting center in the medulla — StatPearls (NCBI)
- Long QT Syndrome — what the QT interval measures — StatPearls (NCBI)
- Opioid-Induced Constipation — fiber and fluid intake — StatPearls (NCBI)
- Rotavirus — ondansetron in acute gastroenteritis — StatPearls (NCBI)
- Lorazepam — anticipatory chemotherapy nausea — StatPearls (NCBI)
- 5-HT3 receptors mediate cytotoxic drug and radiation-evoked emesis (Br J Cancer 1987) — PMC (open access)
- Granisetron for PONV prophylaxis — serotonin release with surgical and anesthetic stress (2026) — PMC (open access)
- Ramosetron for PONV prophylaxis — easier to prevent than to treat (2015) — PMC (open access)
- The use of stems in the selection of INN — -setron, -pitant — World Health Organization
- PDQ® Nausea and Vomiting Related to Cancer Treatment (Health Professional Version) — National Cancer Institute — National Cancer Institute (NCBI Bookshelf)
- Drugs@FDA (openFDA) — dolasetron applications and marketing status — U.S. FDA (openFDA)
- CPIC Guideline for CYP2D6 Genotype and 5-HT3 Receptor Antagonists — 2026 update — Clinical Pharmacology & Therapeutics (PMC, open access)
Reviewed by Hae Suk Lee, RN
Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.